LXEO Covered Call Strategy
LXEO (Lexeo Therapeutics, Inc. Common Stock), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
LXEO (Lexeo Therapeutics, Inc. Common Stock) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $452.3M, a beta of 1.53 versus the broader market, a 52-week range of 2.43-10.99, average daily share volume of 884K, a public-listing history dating back to 2023, approximately 75 full-time employees. These structural characteristics shape how LXEO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.53 indicates LXEO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a covered call on LXEO?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current LXEO snapshot
As of May 15, 2026, spot at $5.09, ATM IV 17.00%, IV rank 0.00%, expected move 4.87%. The covered call on LXEO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this covered call structure on LXEO specifically: LXEO IV at 17.00% is on the cheap side of its 1-year range, which means a premium-selling LXEO covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 4.87% (roughly $0.25 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LXEO expiries trade a higher absolute premium for lower per-day decay. Position sizing on LXEO should anchor to the underlying notional of $5.09 per share and to the trader's directional view on LXEO stock.
LXEO covered call setup
The LXEO covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LXEO near $5.09, the first option leg uses a $5.34 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LXEO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LXEO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $5.09 | long |
| Sell 1 | Call | $5.34 | N/A |
LXEO covered call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
LXEO covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on LXEO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use covered call on LXEO
Covered calls on LXEO are an income strategy run on existing LXEO stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
LXEO thesis for this covered call
The market-implied 1-standard-deviation range for LXEO extends from approximately $4.84 on the downside to $5.34 on the upside. A LXEO covered call collects premium on an existing long LXEO position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether LXEO will breach that level within the expiration window. Current LXEO IV rank near 0.00% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on LXEO at 17.00%. As a Healthcare name, LXEO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LXEO-specific events.
LXEO covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LXEO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LXEO alongside the broader basket even when LXEO-specific fundamentals are unchanged. Short-premium structures like a covered call on LXEO carry tail risk when realized volatility exceeds the implied move; review historical LXEO earnings reactions and macro stress periods before sizing. Always rebuild the position from current LXEO chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on LXEO?
- A covered call on LXEO is the covered call strategy applied to LXEO (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With LXEO stock trading near $5.09, the strikes shown on this page are snapped to the nearest listed LXEO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LXEO covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the LXEO covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 17.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LXEO covered call?
- The breakeven for the LXEO covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LXEO market-implied 1-standard-deviation expected move is approximately 4.87%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on LXEO?
- Covered calls on LXEO are an income strategy run on existing LXEO stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current LXEO implied volatility affect this covered call?
- LXEO ATM IV is at 17.00% with IV rank near 0.00%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.